Literature DB >> 24897032

Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease.

Holger Reinecke1, Michael Nabauer2, Andrea Gerth2, Tobias Limbourg3, Andras Treszl4, Christiane Engelbertz1, Lars Eckardt5, Paulus Kirchhof6, Karl Wegscheider4, Ursula Ravens7, Thomas Meinertz8, Gerhard Steinbeck2, Günter Breithardt1.   

Abstract

Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality but there are few studies available about atrial fibrillation, the most frequent arrhythmia in CKD, and the applied treatment. Based on the prospective German Competence NETwork on Atrial Fibrillation, data of 3138 patients with atrial fibrillation were analyzed and categorized by their estimated glomerular filtration rate (stages 1-3 and 4 plus 5). With advanced CKD, significantly more patients suffered from a more severe form of atrial fibrillation. Despite significantly higher CHADS2 scores in advanced CKD, oral anticoagulation was not prescribed more frequently while antiarrhythmic drugs and catheter ablations were used significantly less often, in contrast to more pacemaker implantations. However, in multivariate hierarchical logistic regression analyses of in-hospital treatments and complications, only hemorrhages and pacemaker implantations turned out to be independently and significantly associated with higher CKD stages. This nationwide study shows that patients with CKD and atrial fibrillation suffer from a markedly higher comorbidity. Thus, while CKD patients have received cardioversions, ablations, antiarrhythmic, or anticoagulation drugs significantly less often in their history, current treatments were not different if adjusted for multiple comorbidities. This might indicate an improvement in the often reported therapeutic nihilism in CKD.

Entities:  

Mesh:

Year:  2014        PMID: 24897032     DOI: 10.1038/ki.2014.195

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

Review 2.  [Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

Authors:  G Schlieper; V Schwenger; A Remppis; T Keller; R Dechend; S Massberg; S Baldus; T Weinreich; G Hetzel; J Floege; F Mahfoud; D Fliser
Journal:  Internist (Berl)       Date:  2017-05       Impact factor: 0.743

3.  Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD.

Authors:  Nisha Bansal; Leila R Zelnick; Kristi Reynolds; Teresa N Harrison; Ming-Sum Lee; Daniel E Singer; Sue Hee Sung; Dongjie Fan; Alan S Go
Journal:  J Am Soc Nephrol       Date:  2021-12-17       Impact factor: 10.121

4.  Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry).

Authors:  Holger Reinecke; Günter Breithardt; Christiane Engelbertz; Roland E Schmieder; Manfred Fobker; Hans O Pinnschmidt; Boris Schmitz; Philipp Bruland; Karl Wegscheider; Hermann Pavenstädt; Eva Brand
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

5.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Mintu P Turakhia; Peter J Blankestijn; Juan-Jesus Carrero; Catherine M Clase; Rajat Deo; Charles A Herzog; Scott E Kasner; Rod S Passman; Roberto Pecoits-Filho; Holger Reinecke; Gautam R Shroff; Wojciech Zareba; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christoph Wanner
Journal:  Eur Heart J       Date:  2018-06-21       Impact factor: 29.983

6.  Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.

Authors:  Akira Mima; Kosuke Tansho; Dai Nagahara; Kenji Watase
Journal:  J Int Med Res       Date:  2018-07-20       Impact factor: 1.671

Review 7.  Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation in Relation to Different Renal Function Levels: A Network Meta-Analysis.

Authors:  Hao Jin; Kongbo Zhu; Lina Wang; Yifan Li; Jingjun Meng; Hong Zhi
Journal:  Cardiovasc Ther       Date:  2020-04-22       Impact factor: 3.023

8.  Chronic kidney disease and cardiovascular mortality in patients with atrial fibrillation: European Society of Hypertension project - ESH A Fib.

Authors:  Vedran Premužić; Ranko Stevanović; Petra Radić; Massimo Salvetti; Martina Lovrić-Benčić; Ana Jelaković; Davor Miličić; Krunoslav Capak; Enrico Agabiti-Rosei; Bojan Jelaković
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

9.  Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.

Authors:  Jeffrey B Washam; DaJuanicia N Holmes; Laine E Thomas; Sean D Pokorney; Elaine M Hylek; Gregg C Fonarow; Kenneth W Mahaffey; Bernard J Gersh; Peter R Kowey; Jack E Ansell; Alan S Go; James A Reiffel; James V Freeman; Daniel E Singer; Gerald Naccarelli; Rosalia Blanco; Eric D Peterson; Jonathan P Piccini
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

10.  Impact of Glomerular Filtration Rate on the Incidence and Prognosis of New-Onset Atrial Fibrillation in Acute Myocardial Infarction.

Authors:  Nicola Cosentino; Marco Ballarotto; Jeness Campodonico; Valentina Milazzo; Alice Bonomi; Simonetta Genovesi; Marco Moltrasio; Monica De Metrio; Mara Rubino; Fabrizio Veglia; Emilio Assanelli; Ivana Marana; Marco Grazi; Gianfranco Lauri; Antonio L Bartorelli; Giancarlo Marenzi
Journal:  J Clin Med       Date:  2020-05-09       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.